<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00467025</url>
  </required_header>
  <id_info>
    <org_study_id>20060159</org_study_id>
    <nct_id>NCT00467025</nct_id>
  </id_info>
  <brief_title>AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With Sorafenib</brief_title>
  <official_title>A Randomized, Double Blinded, Multi-Center Phase 2 Study to Estimate the Efficacy and Evaluate the Safety and Tolerability of Sorafenib in Combination With AMG 386 or Placebo In Subjects With Metastatic Clear Cell Carcinoma of the Kidney</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 2, randomized, double-blind, placebo controlled, multi-center study to&#xD;
      estimate the improvement in progression free survival (PFS) and evaluate the safety and&#xD;
      tolerability of AMG 386 in combination with sorafenib in the treatment of subjects with&#xD;
      advanced clear cell carcinoma of the kidney.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>2 3/4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>2 3/4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>2 3/4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in continuous measures of tumor burden</measure>
    <time_frame>2 3/4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-adjusted area under the curve (AUC) for the FACT-Kidney Cancer Symptom Index (FKSI-15) scale score from baseline through disease progression with imputation for missing data</measure>
    <time_frame>2 3/4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of AEs and significant laboratory changes</measure>
    <time_frame>2 3/4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of the occurrence of anti-AMG 386 antibody formation</measure>
    <time_frame>2 3/4 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">152</enrollment>
  <condition>Advanced Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 386</intervention_name>
    <description>3 mg/kg or 10mg/kg IV weekly until unacceptable toxicity or disease progression</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <description>400 mg PO BID</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 386 placebo IV</intervention_name>
    <description>AMG 386 placebo IV</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects must have a histologically confirmed metastatic RCC with a clear cell&#xD;
             component&#xD;
&#xD;
          -  Low or intermediate risk according to the Memorial Sloan Kettering Cancer Center&#xD;
             (MSKCC) prognostic risk classification.&#xD;
&#xD;
          -  Measurable disease with at least one unidimensionally measurable lesion per RECIST&#xD;
             guidelines with modifications&#xD;
&#xD;
          -  Adequate organ and hematological function as evidenced by laboratory studies conducted&#xD;
             at Screening.&#xD;
&#xD;
          -  ECOG of 0 or 1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Disease Related&#xD;
&#xD;
          -  Known history of central nervous system metastases.&#xD;
&#xD;
          -  Previous treatment (excluding surgery and palliative radiotherapy) for advanced or&#xD;
             metastatic renal cell carcinoma&#xD;
&#xD;
          -  Focal radiation therapy for palliation of pain from bony metastases within 14 days of&#xD;
             randomization.&#xD;
&#xD;
        Medications&#xD;
&#xD;
          -  Currently or previously treated with inhibitors of VEGF.&#xD;
&#xD;
          -  Currently or previously treated with inhibitors of angiopoietin or Tie2.&#xD;
&#xD;
          -  Currently or previously treated with bevacizumab.&#xD;
&#xD;
        General Medical&#xD;
&#xD;
          -  Diagnosis of acute pancreatitis.&#xD;
&#xD;
          -  Myocardial infarction, cerebrovascular accident, transient ischemic attack,&#xD;
             percutaneous transluminal coronary angioplasty/stent, congestive heart failure, grade&#xD;
             2 or greater peripheral vascular disease, arrhythmias not controlled by outpatient&#xD;
             medication, or unstable angina within 1 year prior to randomization&#xD;
&#xD;
          -  Major surgery within 30 days before randomization or still recovering from prior&#xD;
             surgery&#xD;
&#xD;
          -  Uncontrolled hypertension as defined as diastolic &gt; 90 mmHg OR systolic &gt;150 mmHg.&#xD;
             Anti-hypertensive medications are permitted.&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Other investigational procedures are excluded&#xD;
&#xD;
          -  Subject currently is enrolled in or has not yet completed at least 30 days since&#xD;
             ending other investigational device or drug study(s), or subject is receiving other&#xD;
             investigational agent(s)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <removed_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Poland</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>February 2016</verification_date>
  <study_first_submitted>April 26, 2007</study_first_submitted>
  <study_first_submitted_qc>April 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2007</study_first_posted>
  <disposition_first_submitted>April 6, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>April 6, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 27, 2015</disposition_first_posted>
  <last_update_submitted>February 23, 2016</last_update_submitted>
  <last_update_submitted_qc>February 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic clear cell carcinoma of the kidney</keyword>
  <keyword>RCC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Trebananib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

